Created in partnership with individuals living with HS and their dermatologists, this new campaign features stories of those living with HS, informational videos, and interactive tools and resources for those seeking management options, daily care, and information about HS.
Tag Archive for: UCB
Following a delay and an initial rejection, UCB’s IL-17A/IL-17F blocker bimekizumab was approved for moderate-to-severe plaque psoriasis, which will now be marketed with the brand name Bimzelx.
The drug, Zilbrysq is the first once-daily subcutaneous targeted C5 complement inhibitor approved for generalized myasthenia gravis (gMG) and is currently the only self-administered targeting option rare autoimmune disease.
Dealing with the seismic effects of the COVID-19 pandemic, the biopharma industry continues to break new ground during a transformative era of product innovation.